Upstream Bio (NASDAQ:UPB – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Thursday, February 6th. Analysts expect Upstream Bio to post earnings of ($0.62) per share for the quarter.
Upstream Bio (NASDAQ:UPB – Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($6.96) EPS for the quarter, missing the consensus estimate of ($0.58) by ($6.38). The business had revenue of $0.61 million during the quarter, compared to the consensus estimate of $0.83 million. On average, analysts expect Upstream Bio to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Upstream Bio Trading Up 4.1 %
NASDAQ:UPB opened at $10.25 on Thursday. The stock’s 50 day moving average is $16.86. Upstream Bio has a fifty-two week low of $9.29 and a fifty-two week high of $29.46.
Wall Street Analyst Weigh In
View Our Latest Research Report on UPB
About Upstream Bio
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Articles
- Five stocks we like better than Upstream Bio
- What is a support level?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Steel Stocks Soaring After Tariff Announcements
- Why Invest in 5G? How to Invest in 5G Stocks
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Upstream Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upstream Bio and related companies with MarketBeat.com's FREE daily email newsletter.